Webcast ImageWebcast
Q2 2014 Incyte Corporation Earnings Conference Call (Replay)
07/31/14 at 8:30 a.m. ET
Q2 2014 Incyte Corporation Earnings Conference Call
Thursday, July 31, 2014 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

The field of oncology is evolving rapidly and transforming how cancer is treated. We believe Incyte, rooted in rigorous science, is at the center of this transformation. Our pipeline includes innovative compounds in three major oncology areas: onco-inflammation, immuno-oncology and targeted therapies.

We believe our professional and financial resources, our experience and our prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders.


Recent News More >>
DateTitle 
July 31, 2014Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
$84.0 million of 2014 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 55 percent growth over the same period last year 2014 guidance for Jakafi net product revenues increased to range of $330 million to $340 million, driven by strong underlying demand Timely initiation of key pipeline programs, including initiation of two pivotal trials of ruxolitinib in pancreatic cancer and three ... 
Printer Friendly Version
July 30, 2014Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies
Incyte’s investigational oral IDO1 inhibitor INCB24360 to be evaluated with Genentech’s investigational PD-L1 immune checkpoint inhibitor MPDL3280A WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 30, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibit... 
Printer Friendly Version
July 28, 2014Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information
Jakafi is the first and only FDA-approved treatment for patients with intermediate or high-risk myelofibrosis WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 28, 2014-- Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food & Drug Administration (FDA) has approved supplemental labeling for Jakafi® (ruxolitinib) to include new Kaplan-Meier overall survival curves as well as additional safety and dosing information. The new overall surv... 
Printer Friendly Version

2013 Annual Report
2013 Annual Report Download Documentation

2013 10-K

Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.